Abstract
The multi-state procedure, while effective in some ways, has not on the whole met its objective of providing for the free movement of pharmaceutical products within the EC. Flawed legislation and attitude of Member States and industry toward the multi-state procedure have prevented it from leading to a single market. We've learned quite a bit from the multi-state procedure and this knowledge has been applied in developing the proposed decentralized procedure, which will be binding on all Member States.
Get full access to this article
View all access options for this article.